Metadata record for the manuscript: Treatment Scheduling Effects on Evolution of Drug Resistance in Heterogeneous Cancer Cell Populations

Summary This metadata record provides details of the data supporting the claims of the related manuscript: “Treatment Scheduling Effects on Evolution of Drug Resistance in Heterogeneous Cancer Cell Populations”. The related study evaluated crizotinib (ALK/MET inhibitor) and navitoclax (ABT-263; BCL2/BCL-XL inhibitor) combinations in a large design consisting of 696 two-cycle sequential and concomitant treatment regimens with varying treatment dose, duration, and drug holiday length over a 26-day period in MDA-MB-231 TNBC cells. Type of data: DNA barcoding, single-cell RNA sequencing Subject of data: Eukaryotic cell lines Data access All DNA barcoding data and single-cell sequencing data generated in this study have been deposited in the Sequence Read Archive under project accession number https://identifiers.org/ncbi/insdc.sra:SRP259903 (BioProject accession: PRJNA630413). The data underlying Supplementary Figure 3 Panel A & B are openly available from the Cancer Cell Line Encyclopedia (CCLE) at https://portals.broadinstitute.org/ccle. Other datafiles underlying the related manuscript are shared openly as part of this data record. A detailed list of which of these files underlies which manuscript element (figures, supplementary figures, etc) is included in the file ‘Patwardhan_et_al_2021_underlying_data_list.xlsx’. Corresponding author(s) for this study Christos Hatzis, Ph.D., Department of Internal Medicine, Breast Medical Oncology, Yale Cancer Center, Yale University School of Medicine, 300 George Street, New Haven, CT 06511, [e-mail]